Novo Readies Wegovy for Direct-To-Consumer at Discount
5th March 2025
Novo Nordisk is adopting a strategy similar to that of its rival Eli Lilly & Co., preparing to offer its blockbuster weight-loss drug directly to obese US consumers at a discounted rate.
Bloomberg reports that Novo’s Wegovy will be offered directly to cash-paying consumers for $499 per month—significantly lower than the uninsured cost of about $1,350 per month.
Lilly began selling its obesity drug Zepbound directly to patients last year. At the same time, Wegovy’s limited supply drove some customers to compounded versions sold by telehealth companies like Hims & Hers Health Inc., which locked overweight Americans into a monthly subscription model.’
From what I’ve seen, the Eli Lilly drug has fewer side effects.
You still need a prescription.